The objective of this paper is to assist policymakers in developing countries and international donors by providing an outline of economic information needed to make a decision regarding the purchase of drugs to provide highly active antiretroviral therapy (HAART).
The following paper : (i) reviews existing experiences of policymakers in developing countries regarding the purchase of drugs needed for HAART, (ii) identifies issues that would need to be addressed and data that would be required to make more informed decisions regarding this issue, (iii) develops a cost-benefit model that could be utilized in designing an economic research project evaluating the economic costs and benefits of HAART, and (iv) performs a preliminary test of this model with data from Costa Rica.
A review of experiences with this issue reveals that there are growing political, legal and budgetary pressures for countries to make tenable decisions regarding the purchase of drugs for HAART.
An economic model describing the costs and benefits of HAART is proposed, although much of the required data for using such a model is currently neither available or in the process of being collected.
It is imperative that economic data be collected to better inform policymakers in developing countries about their decision regarding the purchase of these drugs. (...)
Mots-clés Pascal : SIDA, Virose, Infection, Chimiothérapie, Traitement, Antiviral, Pays en développement, Politique sanitaire, Aspect économique, Analyse avantage coût, Modélisation, Modèle économique, Homme, Immunopathologie, Immunodéficit, Economie santé, Protocole HAART
Mots-clés Pascal anglais : AIDS, Viral disease, Infection, Chemotherapy, Treatment, Antiviral, Developing countries, Health policy, Economic aspect, Cost benefit analysis, Modeling, Economic model, Human, Immunopathology, Immune deficiency, Health economy
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0025113
Code Inist : 002B05C02D. Création : 31/05/1999.